2 recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow High-risk Myelodysplastic Syndrome: new trials by email Literature Review of High-risk Myelodysplastic Syndrome trials Research Report on High-risk Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS ATRN-119, Decitabine - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-30 | 2026-11-06 |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias CBX-250 - High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Recruiting | Crossbow Therapeutics, Inc. | 72 | 2025-07-16 | 2026-03-16 |
| Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies VIP943 (QW), VIP943 (BIW) - Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Vincerx Pharma, Inc. | 36 | 2023-09-13 | 2024-11-15 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS APG-115, 5-azacitidine - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 69 | 2020-12-04 | 2024-02-01 |
| RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome RVU120(SEL120) - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 1 | Terminated | Ryvu Therapeutics SA | 51 | 2019-09-04 | 2026-09-18 |
| Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias TH-302 - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Threshold Pharmaceuticals | 40 | 2010-06-01 | 2015-05-07 |
Leukemia, Myeloid, Acute (6) · Leukemia (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myelomonocytic, Chronic (2) · Myelodysplastic Syndromes (2) · Bone Marrow Diseases (1) · Burkitt Lymphoma (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (6) · Leukemia, Myeloid (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Hematologic Diseases (5) · Bone Marrow Diseases (4) · Leukemia (4) · Chronic Disease (3) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2)
Azacitidine (1) · Decitabine (1) · TH 302 (1)
Ascentage Pharma Group Inc. (1) · Crossbow Therapeutics, Inc. (1) · Ryvu Therapeutics SA (1) · Threshold Pharmaceuticals (1) · Vincerx Pharma, Inc. (1) · Washington University School of Medicine (1)
United States (6) · Poland (1)
Briggs Morrison, MD (1) · Geoffrey L Uy, MD (1) · Marina Konopleva, MD, PhD (1) · Yifan Zhai, MD, PhD (1)
P50CA171963 (1)